Memphis Shines as Thousands Unite for St. Jude Memphis Marathon Weekend
MEMPHIS, Tenn.–(BUSINESS WIRE)–The spirit of Memphis was on full display this weekend as tens of thousands of runners, patient families, doctors, researchers,... Read more.
Rosen Law Firm Encourages Klarna Group plc Investors to Inquire About Securities Class Action Investigation – KLAR
NEW YORK–(BUSINESS WIRE)–Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf... Read more.
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and published in Blood NEW YORK–(BUSINESS... Read more.
Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting
VGA039 is a once monthly, subcutaneously self-administered therapy for the treatment of bleeding disorders, starting with von Willebrand disease (VWD) Multidose... Read more.
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
– Initial Results from Kite-753, Optimized with Novel Manufacturing Process That Preserves T-Cell Fitness, Show High Complete Response Rate and Favorable Safety... Read more.
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility,... Read more.
Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting
Patients aged 60-75 treated with Orca-T and a reduced intensity conditioning regimen (RIC) experienced low incidence of acute and chronic GvHD with low rates of... Read more.
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with... Read more.
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen... Read more.
NMDP℠ Demonstrates Scientific Leadership in Expanding Patient Access to Lifesaving Cell Therapy at ASH 2025
New results from the Phase II ACCESS trial represent a significant milestone in solving one of transplant medicine’s biggest challenges: finding a donor for every... Read more.